The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies

被引:8
作者
Guo, Haochuan [1 ]
Xu, Xinru [1 ]
Zhang, Jiaxi [1 ]
Du, Yajing [1 ]
Yang, Xinbing [1 ]
He, Zhiheng [2 ,3 ]
Zhao, Linjie [2 ,3 ]
Liang, Tingming [1 ]
Guo, Li [2 ,3 ]
机构
[1] Nanjing Normal Univ, Sch Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China
[2] Nanjing Univ Posts & Telecommun, State Key Lab Organ Elect & Informat Displays, 9 Wenyuan Rd, Nanjing 210023, Peoples R China
[3] Nanjing Univ Posts & Telecommun, Inst Adv Mat IAM, 9 Wenyuan Rd, Nanjing 210023, Peoples R China
基金
中国国家自然科学基金;
关键词
preclinical animal models; anti-cancer therapy; drug development; personalized therapy; REPEAT-DOSE TOXICITY; MOUSE MODELS; GENOMIC INSTABILITY; CYNOMOLGUS MONKEY; CARCINOGENICITY; HALLMARKS; SAFETY; REQUIREMENTS; GENERATION; CHALLENGES;
D O I
10.3390/ph17081048
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The establishment and utilization of preclinical animal models constitute a pivotal aspect across all facets of cancer research, indispensably contributing to the comprehension of disease initiation and progression mechanisms, as well as facilitating the development of innovative anti-cancer therapeutic approaches. These models have emerged as crucial bridges between basic and clinical research, offering multifaceted support to clinical investigations. This study initially focuses on the importance and benefits of establishing preclinical animal models, discussing the different types of preclinical animal models and recent advancements in cancer research. It then delves into cancer treatment, studying the characteristics of different stages of tumor development and the development of anti-cancer drugs. By integrating tumor hallmarks and preclinical research, we elaborate on the path of anti-cancer drug development and provide guidance on personalized cancer therapy strategies, including synthetic lethality approaches and novel drugs widely adopted in the field. Ultimately, we summarize a strategic framework for selecting preclinical safety experiments, tailored to experimental modalities and preclinical animal species, and present an outlook on the prospects and challenges associated with preclinical animal models. These models undoubtedly offer new avenues for cancer research, encompassing drug development and personalized anti-cancer protocols. Nevertheless, the road ahead continues to be lengthy and fraught with obstacles. Hence, we encourage researchers to persist in harnessing advanced technologies to refine preclinical animal models, thereby empowering these emerging paradigms to positively impact cancer patient outcomes.
引用
收藏
页数:30
相关论文
共 50 条
[21]   Development of heparanase inhibitors for anti-cancer therapy [J].
Miao, Hua-Quan ;
Liu, Hu ;
Navarro, Elizabeth ;
Kussie, Paul ;
Zhu, Zhenping .
CURRENT MEDICINAL CHEMISTRY, 2006, 13 (18) :2101-2111
[22]   Helicases as prospective targets for anti-cancer therapy [J].
Gupta, Rigu ;
Brosh, Robert M., Jr. .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (04) :390-401
[23]   The Role of FDA in the Regulation of Anti-Cancer Drugs [J].
Dagher, Ramzi N. ;
Pazdur, Richard .
CURRENT CANCER THERAPY REVIEWS, 2006, 2 (04) :327-329
[24]   Targeting mTOR for Anti-Aging and Anti-Cancer Therapy [J].
Fu, Wencheng ;
Wu, Geng .
MOLECULES, 2023, 28 (07)
[25]   Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products [J].
Zhou, Yalan ;
Peng, Siqi ;
Wang, Huizhen ;
Cai, Xinyin ;
Wang, Qingzhong .
GENES, 2024, 15 (04)
[26]   Drug discovery in prostate cancer mouse models [J].
Valkenburg, Kenneth C. ;
Pienta, Kenneth J. .
EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (09) :1011-1024
[27]   Novel anti-cancer role of naphthazarin in human gastric cancer cells [J].
Kim, Jin-Ah ;
Lee, Eun Kyeong ;
Park, Seong Joon ;
Kim, Nam Deuk ;
Hyun, Dong-Hoon ;
Lee, Chang Geun ;
Lee, Jae Ho ;
Yang, Kwang Mo ;
Heo, Kyu ;
Son, Tae Gen .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (01) :157-162
[28]   Targeting DNA repair, DNA metabolism and replication stress as anti-cancer strategies [J].
Puigvert, Jordi Carreras ;
Sanjiv, Kumar ;
Helleday, Thomas .
FEBS JOURNAL, 2016, 283 (02) :232-245
[29]   Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors [J].
Koga, Yoshikatsu ;
Ochiai, Atsushi .
CELLS, 2019, 8 (05)
[30]   Chromatin-modifying agents in anti-cancer therapy [J].
Seidel, Carole ;
Florean, Cristina ;
Schnekenburger, Michael ;
Dicato, Mario ;
Diederich, Marc .
BIOCHIMIE, 2012, 94 (11) :2264-2279